Profile of patients undergoing third line anti-retroviral therapy
Autor: | T. Jeetenkumar Singh, H. Rebachandra Singh, P Dhileeban Maharajan, L Janani, S. Bhagyabati Devi, Dipul Rudra Paul |
---|---|
Rok vydání: | 2020 |
Předmět: | |
Zdroj: | International Journal of Advances in Medicine. 7:1394 |
ISSN: | 2349-3933 2349-3925 |
Popis: | Background: India has the third largest human HIV epidemic in the world. The advent of antiretroviral drug began a revolution in the management of HIV. Recent studies have shown that an increasing number of patients experiencing virologic failure on second line Antiretroviral therapy and require third line ART.Methods: This prospective cohort study was conducted in Regional Institute of Medical Sciences, Imphal for a period of two years, to study the clinical, immunological, and virological profile of patients undergoing third line Antiretroviral therapy and to study the early immuno-virological response to third line Antiretroviral therapy.Results: Mean CD4 count before third line ART initiation was 95.90±111.85 cells/μl with 60% of them had CD4 count 100000 copies/ml. After one year of third line ART, 80 % of the patients showed viral suppression (VL |
Databáze: | OpenAIRE |
Externí odkaz: |